JP2021531826A5 - - Google Patents

Info

Publication number
JP2021531826A5
JP2021531826A5 JP2021524132A JP2021524132A JP2021531826A5 JP 2021531826 A5 JP2021531826 A5 JP 2021531826A5 JP 2021524132 A JP2021524132 A JP 2021524132A JP 2021524132 A JP2021524132 A JP 2021524132A JP 2021531826 A5 JP2021531826 A5 JP 2021531826A5
Authority
JP
Japan
Prior art keywords
antibody
trop2
optionally substituted
represented
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2021524132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000875 external-priority patent/WO2020016662A2/en
Publication of JP2021531826A publication Critical patent/JP2021531826A/ja
Publication of JP2021531826A5 publication Critical patent/JP2021531826A5/ja
Abandoned legal-status Critical Current

Links

JP2021524132A 2018-07-09 2019-06-26 栄養膜細胞表面抗原2(trop2)に対する特異的な抗体 Abandoned JP2021531826A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695515P 2018-07-09 2018-07-09
US62/695,515 2018-07-09
PCT/IB2019/000875 WO2020016662A2 (en) 2018-07-09 2019-06-26 Antibodies specific to trophoblast antigen 2 (trop2)

Publications (2)

Publication Number Publication Date
JP2021531826A JP2021531826A (ja) 2021-11-25
JP2021531826A5 true JP2021531826A5 (cg-RX-API-DMAC7.html) 2022-06-23

Family

ID=69165234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524132A Abandoned JP2021531826A (ja) 2018-07-09 2019-06-26 栄養膜細胞表面抗原2(trop2)に対する特異的な抗体

Country Status (7)

Country Link
US (1) US20210221907A1 (cg-RX-API-DMAC7.html)
EP (1) EP3821005A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021531826A (cg-RX-API-DMAC7.html)
CN (4) CN114014932A (cg-RX-API-DMAC7.html)
AU (1) AU2019304175A1 (cg-RX-API-DMAC7.html)
TW (1) TW202016148A (cg-RX-API-DMAC7.html)
WO (1) WO2020016662A2 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517114A1 (en) 2014-04-29 2019-07-31 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method and use thereof
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
IL288485B2 (en) * 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
CN114901694A (zh) * 2019-12-31 2022-08-12 启德医药科技(苏州)有限公司 抗trop2抗体、抗体-药物缀合物及其应用
CN115803062B (zh) * 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
CN116589587A (zh) * 2020-06-22 2023-08-15 四川百利药业有限责任公司 一种抗trop2抗体
CN112321715B (zh) * 2020-11-03 2022-05-10 博奥信生物技术(南京)有限公司 抗trop2纳米抗体及其制备方法和应用
IT202000031838A1 (it) * 2020-12-22 2022-06-22 Saverio Alberti Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
CN114685669A (zh) * 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
JP7844499B2 (ja) * 2021-03-08 2026-04-13 ジーンクアンタム ヘルスケア (スーチョウ) シーオー., エルティーディー. 抗体-免疫アゴニストコンジュゲート及びその使用
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
CN115536747B (zh) * 2021-06-30 2024-08-27 益科思特(北京)医药科技发展有限公司 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
CN115558026A (zh) * 2021-07-02 2023-01-03 和迈生物科技有限公司 抗trop2单域抗体及其应用
CN118541392A (zh) * 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
JP2025512426A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド 腫瘍抗原発現がんを治療するための併用療法
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117264062A (zh) * 2022-06-14 2023-12-22 上海恒润达生生物科技股份有限公司 一种特异性结合Trop2的抗体或其抗原结合片段及其制备方法和应用
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024012566A2 (en) * 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118045103B (zh) * 2023-04-10 2025-03-14 英百瑞(杭州)生物医药有限公司 抗Trop2抗体-自然杀伤细胞偶联物及其用途
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
GB202318553D0 (en) * 2023-12-05 2024-01-17 Unikum Therapeutics Aps Engineered plasmacytoid dendritic cells
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401699WA (en) * 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
CA2920192A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
SG10201902571VA (en) * 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
RU2725292C2 (ru) * 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
CN105925536B (zh) * 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 Trop2嵌合抗原受体修饰的T淋巴细胞及其应用
CN107446050A (zh) * 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法

Similar Documents

Publication Publication Date Title
JP2021531825A5 (cg-RX-API-DMAC7.html)
JP2020023523A5 (cg-RX-API-DMAC7.html)
JP2022523710A5 (cg-RX-API-DMAC7.html)
US8513391B2 (en) Monoclonal antibodies for Ebola and Marburg viruses
JP2009225799A5 (cg-RX-API-DMAC7.html)
CN115461364A (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JP2019511212A5 (cg-RX-API-DMAC7.html)
JP2018532383A5 (cg-RX-API-DMAC7.html)
JP2019533475A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2022534297A (ja) 抗b7-h3抗体
JP2020536888A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
JP2022537053A (ja) 抗tigit抗体
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2009517057A5 (cg-RX-API-DMAC7.html)
CN112119099A (zh) 三特异性抗原结合蛋白
RU2015141428A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2019515646A5 (cg-RX-API-DMAC7.html)
JP2020513855A5 (cg-RX-API-DMAC7.html)
CL2010000096A1 (es) Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).
JP2017536341A5 (cg-RX-API-DMAC7.html)
JP2020533004A5 (cg-RX-API-DMAC7.html)
JP2011504740A5 (cg-RX-API-DMAC7.html)
JP2023531185A5 (cg-RX-API-DMAC7.html)